DEVELOPMENT OF A HIGH DIAGNOSTIC AND PROGNOSTIC ACCURACY MODEL FOR THE CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN) BASED ON EARLY BIOMARKERS BY EMPLOYING PROTEOMIC AND BIOINFORMATICS ANALYSIS

Abstract: 

Cervical cancer (CaCx), today the second most frequent cancer in women worldwide, constitutes the culmination of the pre-cancer spectra of cervical intraepithelial neoplasia (CIN) caused by the human papilloma virus (HPV) infection. Nevertheless, once CIN is detected, treatment can be simple, effective, and safe achieving 100% cure and survival rates and, importantly, preserving fertility among young women, the most highly affected by CaCx. Current screening tests have succeeded in decreasing CaCx frequency, but their existing shortcomings, e.g. low sensitivity and low specificity, call for specially educated medical personnel, laboratories employing costly equipment, and specialized biochemists; they moreover frequently generate results that confound the decision-making of patient management. All these factors have impelled the urgent need for the development of a new model of screening test offering reliable and rational diagnosis and prognosis based on multiple biomarkers reflecting the natural history of HPV infection and carcinogenesis.

Our research project goals are to achieve early diagnosis of CIN by a reliable CIN proteomic signature model and consequently to furnish biomarkers validated at the clinical level for individualized therapeutic intervention and exact prognosis.

The project course is as follows:

  • Proteomic signature models for the normal, LSIL, and HSIL stage using liquid phase cytology cervical smear.
  • Identification of proteins and special protein networks for all CIN models.
  • Development of prognostic biomarkers and identification of key proteins and pathways for target treatment for inhibition of CIN advancement to carcinogenesis.
  • Discovery of limited proteomic biomarkers useful for automated diagnostic algorithm with the direct prospect of developing a cost-effective high-accuracy screening test.
  • Development of biomarkers for individualized therapeutic intervention.
  • Development of biomarkers with prognostic value.

Project info

Acronym:
CERVI-CAN-PROT (Cervical Cancer Proteomics)
Scientific Coordinator:
Pappa Kalliopi
Research Team 2 Leader:
Anagnou Nicholas
Research Team 3 Leader:
Agorastos Theodoros

Stats

I.D.:
397
Mis:
383418
Duration (months):
39
Budget:
600 000.00
Diavgeia:
ΑΔΑ: Β4ΘΤ9-Ο36

News